Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

EBOV GP Vaccine

Vaccine (Recombinant protein vaccine) · Immune activation · developed by Novavax

Phase 1 Most advanced trial (none active)

NVAX Developer

1 Registered trials

What is EBOV GP Vaccine?

EBOV GP Vaccine is a vaccine targeting the glycoprotein of Ebola virus, designed to elicit an immune response against Ebola virus infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (Recombinant protein vaccine)
Mechanism: Immune activation
Therapy area: Infectious disease
Developer: Novavax (NVAX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02370589	Phase 1	Ebola	Completed	NVAX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ebola

More from Novavax

CIC Vaccine Phase 3 Fluzone HD Phase 2/3 ICC Vaccine Phase 1/2 NanoFlu Phase 3 NVX-CoV2372 Phase 2 NVX-CoV2373 Phase 3 NVX-CoV2515 Phase 3 NVX-CoV2540 Phase 3 NVX-CoV2601 Phase 2/3 NVX-CoV2705 Phase 3 qNIV Vaccine Phase 2 SARS-CoV-2 rS Phase 1/2

Follow NVAX, the company behind EBOV GP Vaccine

See NVAX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVAX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z